<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02265510</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 52793-101</org_study_id>
    <nct_id>NCT02265510</nct_id>
  </id_info>
  <brief_title>An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies</brief_title>
  <official_title>A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of INCB052793 given to patients with advanced malignancies that will be
      conducted in three phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy) and
      Phase 2 (Combination therapy of INCB052793 with azacitidine and itacitinib with azacitidine).
      Phase 1 will have two parts; a dose escalation (Part 1) and an expansion (Part 2).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events that are defined as dose limiting toxicities occurring during the first cycle of treatment (Phase 1a - 21 days; Phase 1b - 21 or 28 days depending upon treatment regimen )</measure>
    <time_frame>Phase 1a - Baseline through Day 21; Phase 1b - Baseline through Day 21 or 28, depending upon treatment regimen</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Baseline through end of study. Approximately 24 months</time_frame>
    <description>Objective Response Rate determined by investigator evaluation of disease assessments using criteria relevant to the malignancy type</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of INCB052793 (Phase 1a and Phase 1b) and the background standard of care agent(s) (Phase 1b and Phase 2 only)</measure>
    <time_frame>Phase 1a: Day 15 of treatment at a given dose; Phase 1b and Phase 2: Day 5, 8, or 15 of treatment at a given dose, depending upon treatment regimen</time_frame>
    <description>Blood plasma samples will be collected prior to and at 0.5, 1, 2, 4, 6 hours after administration of INCB052793 in Phase 1a, and prior to and at various timepoints from 5 minutes to 8 hours after administration of INCB052793 in Phase 1b and Phase 2, depending upon treatment regimen . Plasma concentrations of INCB052793, the background chemotherapeutic agents (Phase 1b and Phase 2 only) and itacitinib (Phase 2 only) will be determined by the use of validated assays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a, Part 2 only: Plasma concentrations of INCB052793 in the fed state</measure>
    <time_frame>Cycle 2, Day 1 of treatment in this cohort</time_frame>
    <description>Blood plasma samples will be collected prior to and at 0.5, 1, 2, 4, 6 hours after administration of INCB052793 in Phase 1a. Plasma concentrations of INCB052793 will be determined by the use of a validated assay.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Advanced Malignancies</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1a: INCB052793 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: INCB052793 Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: INCB052793 and itacitinib Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB052793</intervention_name>
    <description>Initial cohort dose of INCB052793 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.</description>
    <arm_group_label>Phase 1a: INCB052793 Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency.</description>
    <arm_group_label>Phase 1b: INCB052793 Combination Therapy</arm_group_label>
    <other_name>Gemzar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency.</description>
    <arm_group_label>Phase 1b: INCB052793 Combination Therapy</arm_group_label>
    <other_name>Abraxane®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Dexamethasone administered orally at the protocol-specified dose and frequency.</description>
    <arm_group_label>Phase 1b: INCB052793 Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Carfilzomib administered intravenously at the protocol-specified dose and frequency.</description>
    <arm_group_label>Phase 1b: INCB052793 Combination Therapy</arm_group_label>
    <other_name>Kyprolis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Bortezomib administered intravenously or subcutaneously at the protocol-specified dose and frequency.</description>
    <arm_group_label>Phase 1b: INCB052793 Combination Therapy</arm_group_label>
    <other_name>Velcade®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>Lenalidomide administered orally at the protocol-specified dose and frequency.</description>
    <arm_group_label>Phase 1b: INCB052793 Combination Therapy</arm_group_label>
    <other_name>Revlimid®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azacitidine</intervention_name>
    <description>Azacitidine administered subcutaneously at the protocol-specified dose and frequency.</description>
    <arm_group_label>Phase 1b: INCB052793 Combination Therapy</arm_group_label>
    <arm_group_label>Phase 2: INCB052793 and itacitinib Combination Therapy</arm_group_label>
    <other_name>Vidaza®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB052793</intervention_name>
    <description>INCB052793 tablets administered orally at the protocol specified dose strength and frequency.</description>
    <arm_group_label>Phase 1b: INCB052793 Combination Therapy</arm_group_label>
    <arm_group_label>Phase 2: INCB052793 and itacitinib Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pomalidomide</intervention_name>
    <description>Pomalidomide administered orally at the protocol-specified dose and frequency.</description>
    <arm_group_label>Phase 1b: INCB052793 Combination Therapy</arm_group_label>
    <other_name>Pomalyst®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB050465</intervention_name>
    <description>INCB050465 tablets administered orally at the protocol specified dose strength and frequency.</description>
    <arm_group_label>Phase 1b: INCB052793 Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB039110</intervention_name>
    <description>INCB039110 tablets administered orally at the protocol specified dose strength and frequency.</description>
    <arm_group_label>Phase 2: INCB052793 and itacitinib Combination Therapy</arm_group_label>
    <other_name>itacitinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Phase 1a

          -  Aged 18 years or older

          -  Histologically or cytologically confirmed solid tumor or hematologic malignancy

          -  Life expectancy of 12 weeks or longer

          -  Must have received ≥ 1 prior treatment regimen

          -  Must not be a candidate for potentially curative or standard of care approved therapy

        Phase 1b

          -  Aged 18 years or older

          -  Cohort A: Histologically or cytologically confirmed pancreatic adenocarcinoma,
             triple-negative breast cancer, urothelial cancer with at least 1 measurable or
             evaluable target lesion

          -  Cohorts B, C, D, E and G: Histologically confirmed multiple myeloma and
             measureable/evaluable disease

          -  Cohort F: Confirmed acute myeloid leukemia or myelodysplastic syndrome

          -  Cohort H: Individuals diagnosed with lymphoma

          -  Prior therapy:

               -  Cohort A: No more than 1 prior chemotherapy regimen for advanced or metastatic
                  disease (not including neoadjuvant and/or adjuvant therapy)

               -  Cohorts B, C, D, E and G: Must have relapsed from or have been refractory to ≥ 2
                  prior treatment regimens

               -  Cohort F: May have received any number of prior treatment regimens or be
                  treatment-naïve

               -  Cohort H: Must have relapsed from or have been refractory to available treatments

        Phase 2

          -  Aged 18 years or older

          -  Cohorts I and J: Confirmed acute myeloid leukemia or high risk myelodysplastic
             syndrome

          -  Prior therapy:

               -  Cohorts I and J: Must have failed prior therapy with a hypomethylating agent
                  (HMA)

        Exclusion Criteria:

          -  Prior receipt of a JAK1 inhibitor (Phase 1a only)

          -  Known active central nervous system metastases and/or carcinomatous meningitis

          -  Eastern Cooperative Oncology Group (ECOG) performance status &gt; 2

          -  Any known contraindications to the use of gemcitabine, nab-paclitaxel, dexamethasone,
             carfilzomib, bortezomib, lenalidomide, azacitidine, pomalidomide or PI3Kδ inhibitor
             (Phase 1b and Phase 2 only, as appropriate to treatment cohort)

          -  Known human immunodeficiency virus infection, or evidence of hepatitis B virus (HBV)
             or hepatitis C virus (HCV) infection or risk of reactivation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ekaterine Asatiani, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2014</study_first_submitted>
  <study_first_submitted_qc>October 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2014</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

